Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jeremy Britto

Podiatrist, Foot & Ankle Surgery New Hyde Park, NY Doctor of Podiatric Medicine

NPI 1619356466 CMS profile 5452574

3003 New Hyde Park Rd Ste 312, New Hyde Park, NY 11042

Open in the dashboard

General payments

$16,503

150 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jeremy Britto of New Hyde Park, NY is reported in the CMS Open Payments database as having received $16,503 across 150 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Podiatrist, Foot & Ankle Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,124 64
2024 General $1,604 25
2023 General $1,028 17
2022 General $1,876 10
2021 General $6,551 28
2020 General $976 3
2019 General $345 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jeremy Britto
  • Podiatrist, Foot & Ankle Surgery median
  • Middle half of Podiatrist, Foot & Ankle Surgery
  • National median

In program year 2025, general payments to Jeremy Britto were reported at $4,124. Among 6,994 Podiatrist, Foot & Ankle Surgery profiles paid that year, the median was $424 and the middle half received between $139 and $1,306.

Show as a table
Year Jeremy Britto Podiatrist, Foot & Ankle Surgery median Middle half National median
2019 $345 $389 $118–$1,406 $163
2020 $976 $191 $62–$691 $114
2021 $6,551 $329 $104–$1,341 $132
2022 $1,876 $419 $125–$1,611 $149
2023 $1,028 $377 $128–$1,164 $160
2024 $1,604 $394 $134–$1,168 $164
2025 $4,124 $424 $139–$1,306 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Gotham Surgical Solutions & Devices, Inc. $5,517 11 payments
  2. Stryker Corporation $5,048 52 payments
  3. Arthrex, Inc. $1,520 6 payments
  4. Smith+Nephew, Inc. $914 37 payments
  5. Integra LifeSciences Corporation $773 16 payments
  6. Treace Medical Concepts, Inc. $703 6 payments
  7. PolyNovo North America LLC $536 6 payments
  8. Paragon 28, Inc. $272 2 payments
  9. Acera Surgical, Inc. $241 2 payments
  10. Kerecis Limited $237 2 payments
  11. Other $742 10 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,168 136 payments
  2. Education $5,606 5 payments
  3. Travel and Lodging $2,483 8 payments
  4. Long term medical supply or device loan $245 1 payment
Products named General payments · program years 2019–2025
  1. FLEXBAND $1,076 11 payments
  2. CITREFIX $698 8 payments
  3. PROSTEP $586 8 payments
  4. PRIME SERIES $576 1 payment
  5. NOVOSORB BTM $536 6 payments
  6. Integra Recon-Skin And Wound $527 15 payments
  7. Integra Recon-Skin And Wound $527 15 payments
  8. PRIMATRIX $527 15 payments
  9. Integra Recon-Skin And Wound $527 15 payments
  10. INTEGRA DERMAL REGENERATION TEMPLATE $527 15 payments
  11. Other $9,053 117 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 48 billing codes

Paid by Medicare

$54,193

Of which drugs: $1,345

Medicare patients

135

Average age 75

Services billed

827

72 women, 63 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 68%
Ischemic heart disease 45%
Diabetes 43%
Heart failure 24%
Chronic kidney disease 24%
Atrial fibrillation 21%
Osteoporosis 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 19 30 $3

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

150 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record